Rchr
J-GLOBAL ID:201801011471537977   Update date: Aug. 23, 2024

Domoto Takahiro

ドウモト タカヒロ | Domoto Takahiro
Affiliation and department:
Research field  (2): Tumor diagnostics and therapeutics ,  Tumor biology
Research keywords  (3): 転移 ,  浸潤 ,  分子腫瘍学
Research theme for competitive and other funds  (6):
  • 2022 - 2025 .
  • 2019 - 2022 Exploring the characteristics of tumor-promoting glycometabolism enhanced by GSK3beta toward application to cancer therapy.
  • 2017 - 2019 Exploring biological basis of aberrant cancer energy metabolism induced by GSK3beta toward application to cancer treatment
  • 2015 - 2018 Investigation of biological basis of GSK3beta-targeted therapy and its translation to colorectal cancer treatment
  • 2015 - 2017 Identification and functional analysis of nuclear pore complex components that function to transport beta-catenin between cytoplasm and nucleus
Show all
Papers (31):
  • Masahiro Uehara, Takahiro Domoto, Satoshi Takenaka, Osamu Takeuchi, Takeo Shimasaki, Tomoharu Miyashita, Toshinari Minamoto. Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer. Cancer Drug Resistance. 2024
  • Keita Koizumi, Takahiro Domoto, Toshinari Minamoto, Kazuhito Kazuhito, Hideo Nakajima. Deactivation of glycogen synthase kinase-3β by heat shock-inducible tumor small protein attenuates hyperthermia-induced pro-migratory activity in colorectal cancer cells. International Journal of Oncology. 2023. 63. 2
  • Hiroya Kondo, Kenji Mishiro, Yuki Iwashima, Yujia Qiu, Akiko Kobayashi, Keesiang Lim, Takahiro Domoto, Toshinari Minamoto, Kazuma Ogawa, Munetaka Kunishima, et al. Discovery of a novel aminocyclopropenone compound that Inhibits BRD4-driven nucleoporin NUP210 expression and attenuates colorectal cancer growth. Cells. 2022. 11. 3. 317-317
  • Kensaku Abe, Shingo Shimozaki, Takahiro Domoto, Norio Yamamoto, Hiroyuki Tsuchiya, Toshinari Minamoto. Glycogen synthase kinase 3β biology in bone and soft tissue sarcomas. Journal of Cancer Metastasis and Treatment. 2020. 2020
  • Masahiro Uehara, Takahiro Domoto, Satoshi Takenaka, Dilireba Bolidong, Osamu Takeuchi, Tomoharu Miyashita, Toshinari Minamoto. Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer. Cancer Science. 2020. 111. 12. 4405-4416
more...
MISC (16):
Books (1):
  • 肝胆膵75巻4号 特集:膵がん研究のCutting Edge 「膵がんの増殖,浸潤と治療不応性を繋ぐ治療標的GSK3β」
    2017
Lectures and oral presentations  (39):
  • Potential therapeutic effect of preclinical GSK3β inhibitor in pancreatic cancer with resistance to gemcitabine
    (2023)
  • A new preclinical GSK3β inhibitor overcomes acquired resistance to gemcitabine in pancreatic cancer
    (2023)
  • GSK3β integrates acquired chemoresistance, invasive capacity and tumor stemness in refractory pancreatic cancer
    (2022)
  • GSK3β participates in malignant properties of pancreatic cancer acquiring chemoresistance
    (2022)
  • GSK3β interconnects tumor invasion and stemness in pancreatic cancer acquiring resistance to gemcitabine
    (The 7th JCA-AACR Special Joint Conference The Latest Advances in Pancreatic Research: From Basic Science to Therapeutics 2022)
more...
Professional career (1):
  • 博士(医学) (金沢大学)
Awards (2):
  • 2021/12 - 第32回日本消化器癌発生学会総会/第10回国際消化器癌発生会議 優秀演題賞
  • 2018 - 日本消化器癌発生学会 日本消化器癌発生学会理事長直轄プロジェクト特別推進研究 研究助成
Association Membership(s) (3):
日本消化器癌発生学会 ,  THE JAPANESE CANCER ASSOCIATION ,  日本がん転移学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page